PhRMA deflects on rising drug spending
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- PhRMA is identified by STAT's Health Care Inc newsletter as the pharmaceutical industry's primary lobbying shop, actively working to deflect attention from the "clear-cut rise in prescription drug spending"
- Lobbying groups, per the newsletter, routinely send news releases and talking points to journalists as a standard influence tactic, framing this practice around PhRMA's spending deflection campaign
Why it matters: PhRMA's stated strategy of urging journalists to ignore documented prescription drug spending increases puts the lobby on a collision course with public scrutiny over drug costs — but the full analysis behind STAT's claim sits behind a paywall, limiting independent verification.
